Zafgen, Inc., a Cambridge, MA-based biopharmaceutical company focused on severely obese patients, secured $45m in a Series E equity financing.
Backers included new investors RA Capital Management, Brookside Capital, Venrock, Alta Partners, an undisclosed blue chip investor, and a private investor.
The company intends to use the funds for the continued development of beloranib, its obesity therapeutic.
According to a written note, Zafgen recently reported Phase 2 study results, which demonstrated that beloranib treatment led to significant weight loss and improvements in multiple cardiometabolic risk factors in 147 obese subjects.
Founded in 2005, the company is led by Thomas Hughes, Ph.D., president and chief executive officer.